Date: 2.4.2013
On 23rd February Immunotech Laboratory announced $2M funding approval from its associate Bulgarian Immunotech Partnership Company (Immunotech BG) for clinical trials of the firm’s patented HIV-AIDS medicine.
During the investigation, so-called IPF (Irreversible Pepsin Fraction) drugs will be examined with 50 patients involved. The medicine’s active substance, IPF, is a purified extract of porcine pepsin.
HIV infections are the most susceptible for treatment in their initial stages. However, the problem is that antiretroviral medicines cannot be applied then since drug resistance is very likely to arise. The possible solution is to use non-antiretroviral medicines, but such specifics are lacking...
...read more at
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Cancer cells - Czech Scientists are Working to Find the Achilles‘ Heel of Cancer Cells
Brno University of Technology - university of technology in Brno
Fresh research for fresh air: Harnessing microbes for removing indoor pollutants
In a breakthrough, diabetics damaged cells regenerated to produce insulin